Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion

Lakewood, CO, April 09, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE

KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion

KRTL Holding Group Inc., a diversified international enterprise focused on biotech innovation, regulatory infrastructure, and strategic investment, is pleased to announce the acquisition of Neurogen Brain Balancing, LLC, a California-based neurotechnology company known for its advanced brain balancing therapies and personalized cognitive optimization systems. This transformative acquisition expands KRTL’s presence in the mental wellness space and enhances its position at the intersection of neuroscience, biotechnology, and global healthcare.

This acquisition establishes Neurogen as a subsidiary of KRTL Holding Group Inc., representing a pivotal step in the company’s broader strategy to integrate advanced neurotechnology into its ecosystem and support the growth of scalable mental health solutions.

Under the terms of the transaction, KRTL has acquired 100% of Neurogen’s equity through a stock-based structure that also includes a collaborative profit-sharing agreement. Additional elements of the consideration include KRTL’s commitment to support Neurogen’s entry into new markets and provide FDA-related services to enhance regulatory pathways and strategic growth alignment between the two companies.

“We are thrilled to welcome Neurogen into the KRTL Holding Group family,” said Cesar Herrera, CEO of KRTL Holding Group. “In today’s rapidly evolving global environment, diversification is not just a strategy—it’s a necessity. By bringing Neurogen into our ecosystem, we strengthen our ability to remain agile, resilient, and forward-thinking across multiple sectors. Their innovative work is a natural fit for our mission to invest in businesses that shape the future.”

Neurogen’s proprietary neurotechnology utilizes advanced neuromodulation protocols that support applications ranging from cognitive performance enhancement to stress reduction and post-trauma recovery. The platform is particularly well-positioned to address critical gaps in the continuation of care for patients seeking alternative therapies. By offering non-opioid, non-invasive treatment options with simplified access, the technology aligns with broader healthcare priorities around expanding safe, effective, and accessible behavioral and neurological health interventions.

"This acquisition marks an exciting new chapter for Neurogen. Joining forces with KRTL Holding Group enables us to accelerate our mission of transforming mental health treatment through cutting-edge neurotechnology. With KRTL’s global infrastructure and regulatory expertise, we’re well-positioned to scale our solutions and reach underserved communities worldwide. Together, we aim to expand access to non-invasive, personalized brain health therapies—advancing a new global standard for neurological wellness," said Gregory Gillispie, President of NeuroGen. "The guidance and infrastructure offered by KRTL enhance our ability to grow responsibly while continuing to focus on improving lives through brain balance."


Strategic Integration and Global Expansion Framework

As part of the integration, Neurogen is being incorporated into KRTL’s operational and regulatory infrastructure. These efforts, which include brand alignment across digital channels and investor communications, financial system harmonization, and scalable operational planning, are underway and being informed by both internal leadership and third-party advisors.

KRTL’s internal systems, including its Quality Management System (QMS) and Enterprise Resource Planning (ERP) infrastructure, are currently under expert review. This assessment is aimed at identifying the most effective enhancements to support joint business capabilities and long-term performance.

Further coordination is focused on regulatory and clinical alignment, including FDA-compliant trial design and support for international submissions. Neurogen is also positioned to participate in real-world data research through its connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.

As the collaboration evolves, KRTL intends to issue follow-up announcements that will provide added clarity, updates on integration progress, and forward-looking insights.

About KRTL Holding Group Inc.

KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.

Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.

This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied.

KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements.


www.krtlholding.com
info@krtlholding.com

www.krtlbiotech.com
info@krtlbiotech.com

www.krtl-icc.com
info@krtl-icc.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.